Izvorni znanstveni članak

https://doi.org/10.20471/acc.2021.60.03.04

Synthetic Cannabinoid Bonzai Related Creatine Kinase Enzyme Elevation: a Turkish Center Study

Betul Erismis orcid.org/0000-0003-2970-2076 ; University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Deniz Yilmaz ; University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Ozlem Polat ; University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Family Medicine, Istanbul, Turkey
Hatice Deniz ; University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Mehmet Haluk Yucel ; University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Mehmet Hursitoglu orcid.org/0000-0002-9062-118X ; University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey

Sažetak

Synthetic cannabinoid (locally named ‘Bonzai’ in Turkey) use is increasing worldwide
(especially among people with low income). One of its harmful adverse effects is an increase in
serum levels of muscle enzymes (i.e., creatine kinase [CK]). The aim of this study was to determine the
prevalence of Bonzai use in patients admitted with elevated CK levels and to compare the 1-month
survival status of Bonzai users with that of non-Bonzai users. This retrospective study was conducted
on a total of 468 patients, median (min-max) age 48±22 (18-93) years. It was found that 10.68%
(n=50) of the patients presenting with elevated CK levels were using Bonzai (group 1), while the
remaining
418 (89.32%) patients were non-Bonzai users (group 2). Median age was higher in group
2 as compared with group 1 (p=0.001). In group 1, the predominance of male (M) over female (F)
patients was interestingly high, yielding a F:M ratio of 1/49 (χ2=110.03, p<0.001). The prevalence of
Bonzai use among patients admitted to our center with elevated CK levels was 10.68%. The Bonzai
group patients were younger and mostly males, and none of them died at 1 month of admission. These
findings may help in the management of such clinical conditions and could be a pathfinder for further
studies in this field.

Ključne riječi

Addictive substances; Bonzai; Creatine kinase; Synthetic cannabinoids

Hrčak ID:

271330

URI

https://hrcak.srce.hr/271330

Datum izdavanja:

1.9.2021.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.326 *